DOI QR코드

DOI QR Code

Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis

  • Zhang, Wen-Ying (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) ;
  • Zhang, Wen-Jun (Department of Gerontology, Changhai Hospital, Second Military Medical University) ;
  • Bai, Yu (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) ;
  • Yuan, Hai-Hua (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) ;
  • Liu, Feng (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) ;
  • Gao, Jun (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) ;
  • Gong, Yan-Fang (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) ;
  • Jiang, Bin (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University)
  • Published : 2013.01.31

Abstract

Aims: The aim of this study was to investigate the effects of adjuvant chemotherapy cycles on the prognosis of patients with post-operative stomach cancer through retrospective analysis. Methods: A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles); and Group III (>6 cycles). Results: The 5-year overall survival (OS) was 20.8% in Group I, 45.0% in Group II, and 42.9% in Group III, with a median follow-up of 43 months. The 5-year relapse-free survival (RFS) was 15.1% in Group I, 40% in Group II, and 40% in Group III. The OS and RFS in Groups II and III were significantly better than in Group I (OS, p = 0.002 and p=0.003; RFS, P<0.001 and P=0.002). There was no difference in OS (p = 0.970) or in RFS (p = 0.722) between Groups II and III. Multivariate Cox hazard analysis determined that the number of adjuvant chemotherapy cycles was an independent factor that influenced OS and RFS. Conclusion: Six cycles of adjuvant chemotherapy gave encouraging outcomes in patients with resectable gastric cancer. Further prospective randomized controlled investigations are warranted in a multi-center setting.

Acknowledgement

Supported by : Shanghai Science and Technology Committee Foundation

References

  1. Neri B, Pantaleo P, Giommoni E, et al (2007). Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer, 96, 1043-6. https://doi.org/10.1038/sj.bjc.6603644
  2. Oba K (2009). Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol, 14, 85-9. https://doi.org/10.1007/s10147-009-0877-4
  3. Oh SC (2012). Update of adjuvant chemotherapy for resected gastric cancer. J Gastric Cancer, 12, 3-6. https://doi.org/10.5230/jgc.2012.12.1.3
  4. Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, 649-55. https://doi.org/10.1097/00000421-198212000-00014
  5. Okines A, Verheij M, Allum W, et al (2010). Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, v50-4. https://doi.org/10.1093/annonc/mdq164
  6. Panzini I, Gianni L, Fattori PP, et al (2002). Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori, 88, 21-7.
  7. Paoletti X, Oba K, Burzykowski T, et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 303, 1729-37. https://doi.org/10.1001/jama.2010.534
  8. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20. https://doi.org/10.1056/NEJMoa072252
  9. Saletti P, Berthold D, Ghielmini M, et al (2007). Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma. Hepatogastroenterology, 54, 969-72.
  10. Sasako M, Sakuramoto S, Katai H, et al (2011). Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29, 4387-93. https://doi.org/10.1200/JCO.2011.36.5908
  11. Zhang CX, Huang S, Xu N, et al (2007). Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer. Anticancer Drugs, 18, 581-6. https://doi.org/10.1097/CAD.0b013e3280146296
  12. Zhao SL, Fang JY (2008). The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest, 26, 317-25. https://doi.org/10.1080/07357900701834686
  13. Bang YJ, Kim YW, Yang HK, et al (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, 379, 315-21. https://doi.org/10.1016/S0140-6736(11)61873-4
  14. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20. https://doi.org/10.1056/NEJMoa055531
  15. Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46. https://doi.org/10.1056/NEJMoa073149
  16. Degiuli M, Calvo F (2006). Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary? World J Surg, 30, 2193-203. https://doi.org/10.1007/s00268-006-0179-1
  17. De Vita F, Giuliani F, Orditura M, et al (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol, 18, 1354-8. https://doi.org/10.1093/annonc/mdm128
  18. Di Costanzo F, Gasperoni S, Manzione L, et al (2008). Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst, 100, 388-98. https://doi.org/10.1093/jnci/djn054
  19. Dikken JL, Jansen EP, Cats A, et al (2010). Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol, 28, 2430-6. https://doi.org/10.1200/JCO.2009.26.9654
  20. Jeen YT, Yoon SY, Shin SW, et al (2001). Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer, 91, 2288-93. https://doi.org/10.1002/1097-0142(20010615)91:12<2288::AID-CNCR1260>3.0.CO;2-8
  21. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  22. Kang BW, Kim JG, Chae YS, et al (2011). Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs, 30, 1671-5.
  23. Karacetin D, Incekara O (2004). A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas. J BUON, 9, 263-7.
  24. Kim DH, Oh CA, Oh SJ, et al (2012). Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol, 105, 26-30. https://doi.org/10.1002/jso.22026
  25. Kulig J, Kolodziejczyk P, Sierzega M, et al (2010). Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology, 78, 54-61. https://doi.org/10.1159/000292360
  26. Lim L, Michael M, Mann GB, et al (2005). Adjuvant therapy in gastric cancer. J Clin Oncol, 23, 6220-32. https://doi.org/10.1200/JCO.2005.11.593
  27. Moon YW, Jeung HC, Rha SY, et al (2007). Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol, 14, 2730-7. https://doi.org/10.1245/s10434-007-9479-4
  28. Aoyama T, Yoshikawa T, Watanabe T, et al (2011). Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer, 14, 150-4. https://doi.org/10.1007/s10120-011-0020-x

Cited by

  1. Association between ABCB1 Immunohistochemical Expression and Overall Survival in Gastric Cancer Patients vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6935
  2. Adjuvant Radiotherapy for Gastric Carcinoma: 10 years Follow-up of 244 cases from a Single Institution vol.15, pp.20, 2014, https://doi.org/10.7314/APJCP.2014.15.20.8871